What is William Blair's Forecast for TWST FY2025 Earnings?

Key Points

• William Blair raised its FY2025 earnings per share (EPS) estimate for Twist Bioscience from ($2.14) to ($1.98), indicating a more optimistic outlook for the company.
• In its latest quarterly results, Twist Bioscience reported an EPS of ($0.47), surpassing analyst expectations and generating $96.06 million in revenue.
• Analyst ratings for Twist Bioscience show a trend towards positivity, with an average rating of "Moderate Buy" and a price target of $49.40.

Twist Bioscience Corporation (NASDAQ:TWST - Free Report) - Research analysts at William Blair increased their FY2025 earnings per share (EPS) estimates for Twist Bioscience in a note issued to investors on Tuesday, August 5th. William Blair analyst M. Larew now anticipates that the company will post earnings of ($1.98) per share for the year, up from their previous forecast of ($2.14). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share. William Blair also issued estimates for Twist Bioscience's Q4 2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($1.00) EPS.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.

A number of other analysts have also recently commented on TWST. Evercore ISI set a $46.00 price objective on Twist Bioscience in a research report on Monday. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Guggenheim restated a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Robert W. Baird reduced their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. reduced their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and an average price target of $49.40.

Twist Bioscience Stock Down 5.9%

Twist Bioscience stock opened at $25.90 on Thursday. The stock has a market cap of $1.55 billion, a PE ratio of -17.86 and a beta of 2.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 3.90. Twist Bioscience has a one year low of $25.63 and a one year high of $55.33. The stock has a fifty day moving average of $34.63 and a 200 day moving average of $38.42.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Norges Bank bought a new position in Twist Bioscience during the fourth quarter valued at approximately $7,584,000. Pictet Asset Management Holding SA boosted its stake in Twist Bioscience by 27.7% during the fourth quarter. Pictet Asset Management Holding SA now owns 8,131 shares of the company's stock valued at $378,000 after buying an additional 1,764 shares during the last quarter. Alliancebernstein L.P. boosted its stake in Twist Bioscience by 1.2% during the fourth quarter. Alliancebernstein L.P. now owns 66,524 shares of the company's stock valued at $3,091,000 after buying an additional 820 shares during the last quarter. Geode Capital Management LLC boosted its stake in Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock valued at $63,895,000 after buying an additional 6,908 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new position in Twist Bioscience during the fourth quarter valued at approximately $1,826,000.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Patrick John Finn sold 1,877 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $55,840.75. Following the completion of the transaction, the chief operating officer directly owned 240,783 shares of the company's stock, valued at approximately $7,163,294.25. This trade represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,109 shares of company stock valued at $425,962 over the last 90 days. Company insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.